Anandamide Reduces VCAM-1 and Leukocyte Transmigration in Brain Endothelial Cells
Author Information
Author(s): Mestre Leyre, Iñigo Paula M, Mecha Miriam, Correa Fernando G, Hernangómez-Herrero Miriam, Loría Frida, Docagne Fabian, Borrell José, Guaza Carmen
Primary Institution: Neuroimmunology Group, Functional and Systems Neurobiology Department, Cajal Institute, CSIC, Madrid, Spain
Hypothesis
Does anandamide inhibit VCAM-1 expression and leukocyte transmigration in brain endothelial cells infected with Theiler's virus?
Conclusion
Anandamide inhibits VCAM-1 expression in brain endothelial cells, reducing leukocyte transmigration, which may help in understanding its therapeutic role in multiple sclerosis.
Supporting Evidence
- Anandamide treatment reduced VCAM-1 expression in brain endothelial cells infected with Theiler's virus.
- Leukocyte adhesion to TMEV-infected endothelium was significantly increased, but AEA treatment diminished this adhesion.
- CB1 receptor activation was crucial for the inhibition of VCAM-1 by anandamide.
Takeaway
Anandamide is a substance that helps keep the brain safe by stopping certain cells from getting through the blood-brain barrier when there's an infection.
Methodology
The study used in vitro and in vivo approaches to measure VCAM-1 expression and leukocyte transmigration in brain endothelial cells infected with Theiler's virus.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website